scholarly journals Potentially functional genetic variants in the TNF/TNFR signaling pathway genes predict survival of patients with non‐small cell lung cancer in the PLCO cancer screening trial

2019 ◽  
Author(s):  
Yi Guo ◽  
Yun Feng ◽  
Hongliang Liu ◽  
Sheng Luo ◽  
Jeffrey W. Clarke ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Small Cell Lung Cancer ◽  
Signaling Pathway ◽  
Cell Lung Cancer ◽  
Genetic Variants ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cancer Screening Trial ◽  
Screening Trial

scholarly journals Potentially functional genetic variants in the c-Myb signaling pathway genes are associated with survival of non-small cell lung cancer patients in the PLCO Cancer Screening Trial

2019 ◽  
Author(s):  
Yi Guo ◽  
Yun Feng ◽  
Hongliang Liu ◽  
Sheng Luo ◽  
Patricia G. Moorman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Screening ◽  
Genetic Variants ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cancer Screening Trial ◽  
Nsclc Patients ◽  
Cancer Tissues ◽  
Screening Trial ◽  
Mrna Expression Levels

Abstract Background The c-Myb signaling pathway plays a critical role in regulating expression of genes involved in differentiation, proliferation of cells and cell death, which are related to cancer progression and metastasis. Methods To test the hypothesis that genetic variants in the c-Myb pathway genes are associated with survival of non-small cell lung cancer (NSCLC) patients, we used genotyping data from 1,185 NSCLC patients in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial as the discovery dataset and 984 NSCLC patients in the Harvard Lung Cancer Susceptibility (HLCS) Study as the validation dataset. With genotyping data for 8587 SNPs in 83 genes of the c-Myb pathway from the PLCO dataset, we performed Cox proportional hazards regression analysis to evaluate association between each SNP and survival, and resultant significant SNPs were validated in the HLCS dataset and further evaluated for their functional relevance. Results Specifically, we found that ETS1 rs11606640 GA+AA and ZFHX3 rs62053220 CG+GG genotypes were associated with a favorable overall survival in NSCLC patients (Pdom=0.004 and 0.001, respectively) in a multivariable Cox model. These two validated SNPs were predicted by the RegulomeDB score to be potentially functional. In addition, ETS1 and ZFHX3 mRNA expression levels in lung cancer tissues were significantly lower than that in adjacent normal lung tissues (P<0.05 for both SNPs). Furthermore, the TCGA-based expression quantitative trait loci (eQTL) analysis showed that ETS1 rs11606640 genotypes were significantly associated with their corresponding mRNA expression levels in lung cancer tissues in both additive and recessive models (Padd=0.045 and Prec=0.042), but such a phenotype-genotype correlation for ZFHX3 rs62053220 genotypes was found in only a dominant model (Pdom=0.048). Conclusion We identified two potentially functional SNPs (ETS1 rs11606640 G>A and ZFHX3 rs62053220 C>G) that are associated with survival in NSCLC patients. Additional larger studies are needed to validate our findings.

Phanginin R Induces Cytoprotective Autophagy via JNK/c-Jun Signaling Pathway in Non-Small Cell Lung Cancer A549 Cells

2020 ◽  
Vol 20 (8) ◽  
pp. 982-988 ◽  
Author(s):  
Le-Le Zhang ◽  
Han Bao ◽  
Yu-Lian Xu ◽  
Xiao-Ming Jiang ◽  
Wei Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Signaling Pathway ◽  
Cell Lung Cancer ◽  
Biological Activities ◽  
A549 Cells ◽  
Immunofluorescence Assay ◽  
Small Cell ◽  
Autophagic Flux ◽  
Small Cell Lung

Background: Cassane-type diterpenoids are widely distributed in the medical plants of genus Caesalpinia. To date, plenty of cassane diterpenoids have been isolated from the genus Caesalpinia, and some of them were documented to exhibit multiple biological activities. However, the effects of these compounds on autophagy have never been reported. Objective: To investigate the effects and mechanisms of the cassane diterpenoids including Phanginin R (PR) on autophagy in Non-Small Cell Lung Cancer (NSCLC) A549 cells. Methods: Western blot analysis and immunofluorescence assay were performed to investigate the effects of the compounds on autophagic flux in A549 cells. The pathway inhibitor and siRNA interference were used to investigate the mechanism of PR. MTT assay was performed to detect cell viability. Results: PR treatment upregulated the expression of phosphatidylethanolamine-modified microtubule-associated protein Light-Chain 3 (LC3-II) in A549 cells. Immunofluorescence assay showed that PR treatment increased the production of red-fluorescent puncta in mRFP-GFP-LC3 plasmid-transfected cells, indicating PR promoted autophagic flux in A549 cells. PR treatment activated the c-Jun N-terminal Kinase (JNK) signaling pathway while it did not affect the classical Akt/mammalian Target of Rapamycin (mTOR) pathway. Pretreatment with the JNK inhibitor SP600125 or siRNA targeting JNK or c-Jun suppressed PR-induced autophagy. In addition, cotreatment with the autophagy inhibitor Chloroquine (CQ) or inhibition of the JNK/c-Jun signaling pathway increased PR-induced cytotoxicity. Conclusion: PR induced cytoprotective autophagy in NSCLC A549 cells via the JNK/c-Jun signaling pathway, and autophagy inhibition could further improve the anti-cancer potential of PR.

scholarly journals Exploration in the mechanism of fucosterol for the treatment of non-small cell lung cancer based on network pharmacology and molecular docking

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Xiaoling Li ◽  
Baixin Lin ◽  
Zhiping Lin ◽  
Yucui Ma ◽  
Qu Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Molecular Docking ◽  
Small Cell Lung Cancer ◽  
Signaling Pathway ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Erk Signaling ◽  
Network Pharmacology ◽  
Protein Interaction Data ◽  
Small Cell Lung

AbstractFucosterol, a sterol isolated from brown algae, has been demonstrated to have anti-cancer properties. However, the effects and underlying molecular mechanism of fucosterol on non-small cell lung cancer remain to be elucidated. In this study, the corresponding targets of fucosterol were obtained from PharmMapper, and NSCLC related targets were gathered from the GeneCards database, and the candidate targets of fucosterol-treated NSCLC were predicted. The mechanism of fucosterol against NSCLC was identified in DAVID6.8 by enrichment analysis of GO and KEGG, and protein–protein interaction data were collected from STRING database. The hub gene GRB2 was further screened out and verified by molecular docking. Moreover, the relationship of GRB2 expression and immune infiltrates were analyzed by the TIMER database. The results of network pharmacology suggest that fucosterol acts against candidate targets, such as MAPK1, EGFR, GRB2, IGF2, MAPK8, and SRC, which regulate biological processes including negative regulation of the apoptotic process, peptidyl-tyrosine phosphorylation, positive regulation of cell proliferation. The Raf/MEK/ERK signaling pathway initiated by GRB2 showed to be significant in treating NSCLC. In conclusion, our study indicates that fucosterol may suppress NSCLC progression by targeting GRB2 activated the Raf/MEK/ERK signaling pathway, which laying a theoretical foundation for further research and providing scientific support for the development of new drugs.

scholarly journals ARHGAP10 inhibits the epithelial–mesenchymal transition of non-small cell lung cancer by inactivating PI3K/Akt/GSK3β signaling pathway

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Lan-Lan Lin ◽  
Fan Yang ◽  
Dong-Huan Zhang ◽  
Cong Hu ◽  
Sheng Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Signaling Pathway ◽  
Cell Lung Cancer ◽  
Rho Gtpase ◽  
Epithelial Mesenchymal Transition ◽  
Essential Element ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mesenchymal Transition

Abstract Background Rho GTPase activating protein 10 (ARHGAP10) has been implicated as an essential element in multiple cellular process, including cell migration, adhesion and actin cytoskeleton dynamic reorganization. However, the correlation of ARHGAP10 expression with epithelial–mesenchymal transition (EMT) in lung cancer cells is unclear and remains to be elucidated. Herein, we investigated the relationship between the trait of ARHGAP10 and non-small cell lung cancer (NSCLC) pathological process. Methods Immunohistochemistry was conducted to evaluate the expression of ARHGAP10 in NSCLC tissues. CCK-8 assays, Transwell assays, scratch assays were applied to assess cell proliferation, invasion and migration. The expression levels of EMT biomarkers and active molecules involved in PI3K/Akt/GSK3β signaling pathway were examined through immunofluorescence and Western blot. Results ARHGAP10 was detected to be lower expression in NSCLC tissues compared with normal tissues from individuals. Moreover, overexpression of ARHGAP10 inhibited migratory and invasive potentials of A549 and NCI-H1299 cells. In addition, ARHGAP10 directly mediated the process of EMT via PI3K/Akt/GSK3β pathway. Meanwhile, activation of the signaling pathway of insulin-like growth factors-1 (IGF-1) reversed ARHGAP10 overexpression regulated EMT in NSCLC cells. Conclusion ARHGAP10 inhibits the epithelial–mesenchymal transition in NSCLC via PI3K/Akt/GSK3β signaling pathway, suggesting agonist of ARHGAP10 may be an optional remedy for NSCLC patients than traditional opioids.

Sign in / Sign up

Export Citation Format

Share Document